{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:12:04Z","timestamp":1785553924319,"version":"3.56.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In tropical and subtropical countries, 4 dengue viruses (DENVs) produce mild disease and a potentially fatal vascular permeability syndrome. Unique antigenic and biological properties of DENVs contribute to vaccine development delays. Three tissue culture\u2013based tetravalent candidate dengue vaccines have advanced to phase 3 clinical testing. Sanofi-Pasteur\u2019s chimeric yellow fever tetravalent dengue vaccine, Dengvaxia, licensed in 19 dengue-endemic countries, Europe, and the United States, partially protects seropositives but sensitizes some seronegatives to severe hospitalized dengue. During 2 years of phase 3, Takeda\u2019s TAK-003, a chimeric DENV 2 tetravalent vaccine, protected against DENV 2 but was less protective against other DENVs. In seronegative adults, 1 dose of a tetravalent nonstructural deletion mutant vaccine in late phase developed by the US National Institutes of Health protected seronegative humans against challenge with DENVs 2 and 3. This experience suggests nearly whole DENV genomes are required to achieve balanced and sustained protective immunity.<\/jats:p>","DOI":"10.1093\/cid\/ciab282","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T19:11:32Z","timestamp":1617045092000},"page":"156-160","source":"Crossref","is-referenced-by-count":17,"title":["Is Dengue Vaccine Protection Possible?"],"prefix":"10.1093","volume":"74","author":[{"given":"Scott B","family":"Halstead","sequence":"first","affiliation":[{"name":"Independent Consultant, 5824 Edson Lane, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"2022011123264123600_CIT0001","volume-title":"Dengue: guidelines for diagnosis, treatment prevention and control","author":"World Health Organization","year":"2009"},{"key":"2022011123264123600_CIT0002","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch Virol"},{"key":"2022011123264123600_CIT0003","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0022-3476(66)80249-4","article-title":"Shock associated with dengue infection. I. Clinical and physiologic manifestations of dengue hemorrhagic fever in Thailand, 1964","volume":"68","author":"Cohen","year":"1966","journal-title":"J Pediatrics"},{"key":"2022011123264123600_CIT0004","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1056\/NEJM197311082891902","article-title":"The potential pathogenic role of complement in dengue hemorrhagic shock syndrome","volume":"289","author":"Bokisch","year":"1973","journal-title":"N Engl J Med"},{"key":"2022011123264123600_CIT0005","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.celrep.2019.01.036","article-title":"Flavivirus NS1 triggers tissue-specific vascular endothelial dysfunction reflecting disease tropism","volume":"26","author":"Puerta-Guardo","year":"2019","journal-title":"Cell Reports"},{"key":"2022011123264123600_CIT0006","doi-asserted-by":"crossref","first-page":"e1006220","DOI":"10.1371\/journal.ppat.1006220","article-title":"OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans","volume":"13","author":"Sierra","year":"2017","journal-title":"PLoS Pathog"},{"key":"2022011123264123600_CIT0007","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","article-title":"Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes","volume":"10","author":"Halstead","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2022011123264123600_CIT0008","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1128\/CVI.00316-10","article-title":"How innate immune mechanisms contribute to antibody-enhanced viral infections","volume":"17","author":"Ubol","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"2022011123264123600_CIT0009","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/JVI.00220-10","article-title":"Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection","volume":"85","author":"Boonnak","year":"2011","journal-title":"J Virol"},{"key":"2022011123264123600_CIT0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.12688\/gatesopenres.12844.3","article-title":"Scaled deployment of Wolbachia to protect the community from dengue and other Aedes transmitted arboviruses","volume":"2","author":"O\u2019Neill","year":"2018","journal-title":"Gates Open Res"},{"key":"2022011123264123600_CIT0011","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4269\/ajtmh.14-0132","article-title":"Review article: research on dengue during World War II revisited","volume":"91","author":"Snow","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0012","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4269\/ajtmh.1974.23.974","article-title":"Etiologies of the experimental dengues of Siler and Simmons","volume":"23","author":"Halstead","year":"1974","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0013","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/infdis\/jit436","article-title":"A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand","volume":"209","author":"Anderson","year":"2014","journal-title":"J Infect Dis"},{"key":"2022011123264123600_CIT0014","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4269\/ajtmh.2007.77.910","article-title":"Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences","volume":"77","author":"Gibbons","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4269\/ajtmh.1973.22.375","article-title":"Studies on the immunization of monkeys against dengue: II. Protection following inoculation of combinations of viruses","volume":"22","author":"Halstead","year":"1973","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0016","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022011123264123600_CIT0017","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4269\/ajtmh.1963.12.620","article-title":"Attenuated living Type 1 dengue vaccines","volume":"12","author":"Wisseman","year":"1963","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0018","first-page":"93","article-title":"Report of dengue vaccine trial in the Caribbean, 1963: a collaborative study","volume":"35","author":"Bellanti","year":"1966","journal-title":"Bull World Health Organ"},{"issue":"Pt 10","key":"2022011123264123600_CIT0019","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1099\/0022-1317-71-10-2301","article-title":"Attenuation of wild-type yellow fever virus by passage in HeLa cells","volume":"71","author":"Barrett","year":"1990","journal-title":"J Gen Virol"},{"key":"2022011123264123600_CIT0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690005","article-title":"Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii","volume":"69","author":"Halstead","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690001","article-title":"Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command","volume":"69","author":"Innis","year":"2003","journal-title":"Amer J Trop Med Hyg"},{"key":"2022011123264123600_CIT0022","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0023","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4269\/ajtmh.14-0625","article-title":"A phase II, randomized, safety and immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and adults living in Puerto Rico","volume":"93","author":"Bauer","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0024","first-page":"20","article-title":"Short history of dengue and Mahidol dengue vaccine","volume":"48","author":"Yoksan","year":"2017","journal-title":"South East Asian J Trop Med Pub Health"},{"key":"2022011123264123600_CIT0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","article-title":"Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses","volume":"66","author":"Sabchareon","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0026","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1016\/j.vaccine.2006.03.066","article-title":"Innate and adaptive cellular immunity in flavivirus-na\u00efve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)","volume":"24","author":"Sanchez","year":"2006","journal-title":"Vaccine"},{"key":"2022011123264123600_CIT0027","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4269\/ajtmh.1984.33.684","article-title":"Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells","volume":"33","author":"Eckels","year":"1984","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0028","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1128\/jvi.70.6.4162-4166.1996","article-title":"Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge","volume":"70","author":"Bray","year":"1996","journal-title":"J Virol"},{"key":"2022011123264123600_CIT0029","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","article-title":"Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine","volume":"75","author":"Guirakhoo","year":"2001","journal-title":"J Virol"},{"key":"2022011123264123600_CIT0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"2022011123264123600_CIT0031","first-page":"341","article-title":"Global Advisory Committee on Vaccine Safety, 15\u201316 June 2016","volume":"91","author":"World Health Organization","year":"2016","journal-title":"Weekly Epidemiological Record"},{"key":"2022011123264123600_CIT0032","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"2022011123264123600_CIT0033","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.vaccine.2020.06.079","article-title":"Ethics of a partially effective dengue vaccine: lessons from the Philippines","volume":"38","author":"Halstead","year":"2020","journal-title":"Vaccine"},{"key":"2022011123264123600_CIT0034","doi-asserted-by":"crossref","first-page":"e2243","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2022011123264123600_CIT0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0264-410X(95)00167-Y","article-title":"Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers","volume":"14","author":"Vaughn","year":"1996","journal-title":"Vaccine"},{"key":"2022011123264123600_CIT0036","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"2022011123264123600_CIT0037","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3\u2019-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"2022011123264123600_CIT0038","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022011123264123600_CIT0039","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1128\/JVI.00273-15","article-title":"Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies","volume":"89","author":"Tsai","year":"2015","journal-title":"J Virol"},{"key":"2022011123264123600_CIT0040","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02147-16","article-title":"Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity","volume":"91","author":"Angelo","year":"2017","journal-title":"J Virol"},{"key":"2022011123264123600_CIT0041","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1590\/s1678-9946201860043","article-title":"Dengue in Brazil in 2017: what happened?","volume":"60","author":"Lopes","year":"2018","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2022011123264123600_CIT0042","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jiv289","article-title":"Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets","volume":"212","author":"Weiskopf","year":"2015","journal-title":"J Infect Dis"},{"issue":"Pt 3","key":"2022011123264123600_CIT0043","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/0022-1317-68-3-853","article-title":"Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1","volume":"68","author":"Schlesinger","year":"1987","journal-title":"J Gen Virol"},{"key":"2022011123264123600_CIT0044","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3201\/eid0812.020170","article-title":"Dengue hemorrhagic fever in infants: research opportunities ignored","volume":"8","author":"Halstead","year":"2002","journal-title":"Emerg Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab282\/41716813\/ciab282.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/1\/156\/42107076\/ciab282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/1\/156\/42107076\/ciab282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T23:30:38Z","timestamp":1641943838000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/74\/1\/156\/6206739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2022,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab282","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,3,31]]}}}